Shockwave Medical (SWAV) Tops Q4 EPS by 27c, provides guidance

Shockwave Medical (NASDAQ: SWAV) reported Q4 EPS of $1.16, $0.27 better than the analyst estimate of $0.89. Revenue for the quarter came in at $203 million versus the consensus estimate of $199.45 million.

GUIDANCE:

Shockwave Medical sees FY2024 revenue of $910-930 million, versus the consensus of $918.9 million.

For earnings history and earnings-related data on Shockwave Medical (SWAV) click here.

You May Also Be Interested In

• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance